 |
|
|
|
|
|
|
|
 |
Results for 'Competitor Analysis: Insulin' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Erythropoietin (EPO)
Competitor Analysis
|
July 2008 |
£255 |
70 % |
Dragon Pharmaceutical Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Dr Reddys Laboratories Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Dov Pharmaceutical Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Duska Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Dyax Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
EPIX Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Dynavax Technologies Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Dnaprint Genomics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Diamyd Medical AB -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
DUSA Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
DURECT Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
DRAXIS Health Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Dendreon Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Depomed Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Echo Therapeutics, Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Derma Sciences Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Discovery Laboratories Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Eisai Co Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Enzo Biochem Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
EntreMed Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Enhance Biotech Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Enzon Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
EpiCept Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Eqitx Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Epigenomics AG -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Endovasc Inc (NV) -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Endo Pharmaceuticals Holdings Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Eli Lilly & Co -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Elan Corp Plc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Elite Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Emergent BioSolutions Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Encysive Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Emisphere Technologies Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
DOR BioPharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
DENTSPLY International Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cobalis Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Clinuvel Pharmaceuticals Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Clinical Data Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
CollaGenex Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Columbia Laboratories Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Compugen Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
CombinatoRx Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cleveland Biolabs Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Chugai Pharmaceutical Co Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cerus Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Ceragenix Phamaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Chattem Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Chelsea Therapeutics International Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Chemokine Therapeutics Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Chemgenex Pharmaceuticals Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Corcept Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cortex Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
CytRx Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cypress Bioscience Incorporated -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cyplasin Biomedical Ltd. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
CytoDyn Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cytogenix Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cytos Biotechnology AG -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cytokinetics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cyclacel Pharmaceuticals, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cyanotech Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Critical Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cougar Biotechnology, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Crucell N V -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cubist Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Curis Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
CuraGen Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Eugene Science Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Eurand N.V. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Imarx Therapeutics, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Imagenetix Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Idera Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Imclone Systems Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Immtech Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Immunomedics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
ImmunoGen Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Idenix Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
ISTA Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Hospira Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Hologic Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Human Genome Sciences Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
ICAgen Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
IMCOR Pharmaceutical Co. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
IDM Pharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Impax Laboratories Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
InNexus Biotechnology Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
IntelGenx Technologies Corp. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Inspire Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Insmed Incorporated -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Intellect Neurosciences, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
InterMune Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Introgen Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Interpharm Holdings Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Inovio Biomedical Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Innovive Pharmaceuticals, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Incyte Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
InSite Vision Incorporated -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Indevus Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Infinity Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Inhibitex Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Inflazyme Pharmaceuticals Ltd. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Hollis -Eden Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Hi -Tech Pharmacal Co Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
GammaCan International Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
GW Pharmaceuticals PLC -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
GTX INC -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Gedeon Richter Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
GelStat Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Genaera Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
GenVec Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
GTC Biotherapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
GPC Biotech AG -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Favrille Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Exelixis Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Flamel Technologies SA ADS -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Forbes Medi -Tech Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Forticell Bioscience, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Forest Laboratories Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Genelabs Technologies Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Genentech Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
H.Lundbeck AS -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
GlaxoSmithKline plc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Gilead Sciences Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Hana Biosciences Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Helix BioMedix Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Hemobiotech Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Hemispherx Biopharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Geron Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
GeoVax Labs Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Genitope Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Generex Biotechnology Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Genta Incorporated -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Gentium S.p.A -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
GeoPharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Genzyme Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cephalon Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Celsion Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Alpharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
AlphaRx Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Alnylam Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Alseres Pharmaceuticals, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Altus Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Amarin Corporation plc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Amarillo Biosciences Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Allos Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Alliance Pharmaceutical Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Alexza Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Alexion Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Alfacell Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Alkermes Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Allergy Therapeutics plc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Allergan Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Amazon Biotech Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Amdl Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Antisoma PLC -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Antigenics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Antares Pharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
ArQule Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Aradigm Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Ardea Biosciences, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Arana Therapeutics Limited -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Anika Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Angiotech Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Amicus Therapeutics, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Amgen Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Amylin Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Anadys Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Anesiva, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Anavex Life Sciences Corp. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Alcon Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Alchemia Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
AXM Pharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
AVI BioPharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
AVAX TECHNOLOGIES INCORPORATED -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Aastrom Biosciences Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Abbott Laboratories -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Acambis plc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Acadia Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
AVANT Immunotherapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
AVANIR Pharmaceuticals -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
AEterna Zentaris Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
ADVENTRX Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
AMAG Pharmaceuticals, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
AP Pharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
ARYx Therapeutics, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
APP Pharmaceuticals, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Accentia Biopharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Access Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Aeolus Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Advaxis Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Advanced Life Sciences Holdings Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Affymax Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
AiDA Pharmaceuticals, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Akorn Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Akesis Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Adolor Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Adherex Technologies Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Acorda Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Achillion Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Actelion Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Acura Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Adams Respiratory Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Acusphere Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Arena Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Ariad Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Biovail Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Biotech Holdings Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Biosyntech Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Biovest International Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Bradley Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Bristol -Myers Squibb Company -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Brainstorm Cell Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Biopure Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Biophage Pharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
|
Biocon Ltd -Therapeutic Competitors< |
